"サノフィ" の関連情報検索結果
News
Q&A
Shopping
Auction
Rakuten
amazonNo Christmas present for Sanofi, as FDA turns down MS drug - pharmaphorum
No Christmas present for Sanofi, as FDA turns down MS drug pharmaphorum
Sanofi Acquires Emeryville's Dynavax Technologies for $2.2 Billion, Bolstering Vaccine Portfolio ...
Where is Sanofi (SNY) Headed According to Wall Street? - Yahoo Finance
Where is Sanofi (SNY) Headed According to Wall Street? Yahoo Finance
Sanofi Acquires Dynavax Technologies to Expand Vaccine Portfolio with Hepatitis B and Shingles Ca...
Sanofi Acquires Dynavax Technologies to Expand Vaccine Portfolio with Hepatitis B and Shingles Candidates geneonline.com
Sanofi stock outlook dims as TD Cowen reiterates Hold rating - Investing.com
Sanofi stock outlook dims as TD Cowen reiterates Hold rating Investing.com
Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax - Fie...
Acquisitive Sanofi keeps deals coming, laying out $2.2B for hepatitis vaccine maker Dynavax Fierce Pharma
Sanofi reduces valuation after R&D setbacks - marketscreener.com
Sanofi reduces valuation after R&D setbacks marketscreener.com
Sanofi acquires vaccine company for over USD 2 billion - medwatch.com
Sanofi acquires vaccine company for over USD 2 billion medwatch.com
Emeryville's Dynavax accepts $2.2 billion buyout from Sanofi following year of investor pressure ...
Emeryville's Dynavax accepts $2.2 billion buyout from Sanofi following year of investor pressure The Business Journals
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal - The Wall Street Journal
Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal The Wall Street Journal
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal - Reuters
Sanofi pushes ahead on adult vaccines with $2.2 billion Dynavax deal Reuters
This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. - Barron's
This Biotech Stock Soars 39%. Sanofi Is Buying It for $2.2 Billion. Barron's
Sanofi MS drug hits two setbacks - BioPharma Dive
Sanofi MS drug hits two setbacks BioPharma Dive
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang - Yahoo Finance
Jefferies Maintains Buy on Sanofi (SNY) Despite Regulatory Overhang Yahoo Finance
Sanofi stock outlook dims as TD Cowen lowers tolebrutinib sales forecast - Investing.com
Sanofi stock outlook dims as TD Cowen lowers tolebrutinib sales forecast Investing.com
Sanofi swoops on Dynavax with $2.5bn takeover deal - pharmaphorum
Sanofi swoops on Dynavax with $2.5bn takeover deal pharmaphorum
Sanofi buys hep B vaccine maker for $2.2bn - Yahoo Finance
Sanofi buys hep B vaccine maker for $2.2bn Yahoo Finance
Jefferies reiterates Buy rating on Sanofi stock, maintains EUR100 price target - Investing.com
Jefferies reiterates Buy rating on Sanofi stock, maintains EUR100 price target Investing.com
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) - Yahoo Finance
Sanofi (SNY) to Acquire Dynavax Technologies Corporation (DVAX) Yahoo Finance
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection - Yahoo Finance Singapore
Sanofi Agrees to Buy Dynavax for $2.2 Billion After FDA MS Drug Rejection Yahoo Finance Singapore
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Yahoo Finance
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise Yahoo Finance
Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall - Reuters
Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall Reuters
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while stre...
Press Release: Sanofi reaches agreement with the US government to lower medicine costs while strengthening innovation Yahoo Finance
Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk (NASDAQ:SNY) - Seeking Alpha
Sanofi-Dynavax: A Conservative Vaccine Deal With Upside Tail Risk (NASDAQ:SNY) Seeking Alpha
Sanofi to pay Dren Bio up to $1.7 billion to develop autoimmune disease therapies - Reuters
Sanofi to pay Dren Bio up to $1.7 billion to develop autoimmune disease therapies Reuters
JP Morgan 2026 Preview: Sanofi Looks to Bolster Future Pipeline - Pharmaceutical Executive
JP Morgan 2026 Preview: Sanofi Looks to Bolster Future Pipeline Pharmaceutical Executive
Sanofi signs $1B biobucks pact for Alzheimer's asset in 2nd biotech deal of the day - Fierce Biotech
Sanofi signs $1B biobucks pact for Alzheimer's asset in 2nd biotech deal of the day Fierce Biotech
Sanofi Buys Dynavax for $2.2 Billion to Boost Vaccine Lineup - Bloomberg.com
Sanofi Buys Dynavax for $2.2 Billion to Boost Vaccine Lineup Bloomberg.com
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition - MedCity News
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition MedCity News
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts - Fierce Biotech
Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts Fierce Biotech
Patient Engagement: Informing & Empowering Patients - Sanofi
Our Environmental Impact - Sanofi
Our Environmental Impact Sanofi
Sanofi's tolebrutinib woes pile up with FDA delay, trial miss - Fierce Biotech
Sanofi's tolebrutinib woes pile up with FDA delay, trial miss Fierce Biotech
US FDA rejects Sanofi filing for tolebrutinib in progressive MS - The Pharma Letter
US FDA rejects Sanofi filing for tolebrutinib in progressive MS The Pharma Letter
Sanofi to Buy Dynavax in $2.2 Billion Push Into Adult Vaccines - TipRanks
Sanofi to Buy Dynavax in $2.2 Billion Push Into Adult Vaccines TipRanks
Sanofi India Gets Tax Demand Order Worth 14.3 Million Rupees - TradingView — Track All Markets
Sanofi India Gets Tax Demand Order Worth 14.3 Million Rupees TradingView — Track All Markets
Dynavax Agrees to Be Acquired by Sanofi in Merger - TipRanks
Watch Sanofi to Buy Dynavax to Boost Vaccines Business - Bloomberg.com
Watch Sanofi to Buy Dynavax to Boost Vaccines Business Bloomberg.com
Sanofi to acquire vaccine maker Dynavax - The Pharma Letter
Sanofi to acquire vaccine maker Dynavax The Pharma Letter
Sanofi to buy vaccine maker Dynavax for $2.2B - FirstWord Pharma
Sanofi to buy vaccine maker Dynavax for $2.2B FirstWord Pharma
Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies - Fierce Biotech
Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies Fierce Biotech
Sanofi To Buy Vaccine Maker Dynavax For $2.2 Billion - Investor's Business Daily
Sanofi To Buy Vaccine Maker Dynavax For $2.2 Billion Investor's Business Daily
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership - BioSpace
Sanofi Taps Dren Again in up to $1.7B Autoimmune Partnership BioSpace
Sanofi Wins First-Ever EU Approval for BTK Inhibitor Wayrilz in Immune Thrombocytopenia - TipRanks
Sanofi Wins First-Ever EU Approval for BTK Inhibitor Wayrilz in Immune Thrombocytopenia TipRanks
Sanofi says rejection of tolebrutinib is "significant" change in direction from FDA - FirstWord P...
Sanofi says rejection of tolebrutinib is "significant" change in direction from FDA FirstWord Pharma
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi - Reuters
South Korea's ADEL signs up to $1.04 billion Alzheimer's drug development deal with Sanofi Reuters
Dynavax Technologies Signs Agreement and Plan of Merger With Sanofi - TradingView — Track All Mar...
Dynavax Technologies Signs Agreement and Plan of Merger With Sanofi TradingView — Track All Markets
DVAX Stock Today: Sanofi’s $2.2B Buyout Sharpens Vaccine Push — December 26 - Meyka
DVAX Stock Today: Sanofi’s $2.2B Buyout Sharpens Vaccine Push — December 26 Meyka
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion - Yahoo Finance
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion Yahoo Finance
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application - BioSpace
Sanofi’s MS Drug Fails Phase III Trial, While FDA Again Delays Approval Application BioSpace
Sanofi Hit by FDA Rebuff on Tolebrutinib MS Filing but Sees No Change to 2025 Outlook - TipRanks
Sanofi Hit by FDA Rebuff on Tolebrutinib MS Filing but Sees No Change to 2025 Outlook TipRanks
Sanofi Acquires Hepatitis B Vaccine Manufacturer in $2.2 Billion Deal - geneonline.com
Sanofi Acquires Hepatitis B Vaccine Manufacturer in $2.2 Billion Deal geneonline.com
What Sanofi Is Getting Through The Acquisition Of Dynavax (NASDAQ:SNY) - Seeking Alpha
What Sanofi Is Getting Through The Acquisition Of Dynavax (NASDAQ:SNY) Seeking Alpha
Sanofi- Cell Research outstanding paper award of 2024 - Nature
Sanofi- Cell Research outstanding paper award of 2024 Nature
Why Wall Street Analysts Are Closely Watching Sanofi (SNY) - Yahoo Finance
Why Wall Street Analysts Are Closely Watching Sanofi (SNY) Yahoo Finance
Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B - Law360
Sanofi Buys Hepatitis Vaccine Maker Dynavax For $2.2B Law360
Sanofi agrees to acquire DynaVax for $2.2 bln, adds hepatitis B vaccine - MLex
Sanofi agrees to acquire DynaVax for $2.2 bln, adds hepatitis B vaccine MLex
Press Release: Sanofi to acquire Dynavax, adding a marketed - GlobeNewswire
Press Release: Sanofi to acquire Dynavax, adding a marketed GlobeNewswire
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio - Yahoo Finance
Sanofi to Acquire Dynavax for $2.2 Billion, Expanding Vaccine Portfolio Yahoo Finance
Delayed MS Decision and Trial Miss Add to Sanofi’s R&D Challenges - Insider Monkey
Delayed MS Decision and Trial Miss Add to Sanofi’s R&D Challenges Insider Monkey
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion ...
Dren Bio Expands Strategic Collaboration with Sanofi to Develop Next-Generation B-Cell Depletion Therapy Business Wire
‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech tran...
‘Oscotec proves competitiveness in targeting tau protein for Alzheimer’s treatment with tech transfer to Sanofi’ koreabiomed.com
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years ...
Press Release: Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthma Yahoo Finance
Press Release : Sanofi provides update on tolebrutinib - GlobeNewswire
Press Release : Sanofi provides update on tolebrutinib GlobeNewswire
Greenup Street Wealth Management LLC Invests $2.06 Million in Sanofi $SNY - MarketBeat
Greenup Street Wealth Management LLC Invests $2.06 Million in Sanofi $SNY MarketBeat
Dynavax Stock (+38%) : Sanofi Buyout Validates Vaccine Pipeline - Trefis
Dynavax Stock (+38%) : Sanofi Buyout Validates Vaccine Pipeline Trefis
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies - Fi...
The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies FinancialContent
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases -...
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Yahoo Finance
Sanofi receives FDA complete response letter for MS drug tolebrutinib - Investing.com
Sanofi receives FDA complete response letter for MS drug tolebrutinib Investing.com
FDA Is Bearer Of Bad Tidings For Sanofi’s Tolebrutinib - Citeline News & Insights
FDA Is Bearer Of Bad Tidings For Sanofi’s Tolebrutinib Citeline News & Insights
Is Sanofi Now an Opportunity After Recent R and D and Portfolio Reshaping Moves? - Yahoo Finance
Is Sanofi Now an Opportunity After Recent R and D and Portfolio Reshaping Moves? Yahoo Finance
Sanofi Snaps Up Dynavax For $2.2bn In Vaccine Business Push - Citeline News & Insights
Sanofi Snaps Up Dynavax For $2.2bn In Vaccine Business Push Citeline News & Insights
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion - 1470 & 100.3 WMBD
Sanofi to acquire hepatitis B vaccine maker Dynavax for $2.2 billion 1470 & 100.3 WMBD
Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B, gets CRL for MS drug - Endpoints News
Sanofi to buy hepatitis B vaccine maker Dynavax for $2.2B, gets CRL for MS drug Endpoints News
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise - Zacks Investment Research
Sanofi to Buy Dynavax for $2.2B to Boost Adult Vaccine Franchise Zacks Investment Research
Stock Movers: BP, Sanofi, Fresnillo - Bloomberg.com
Stock Movers: BP, Sanofi, Fresnillo Bloomberg.com
Press Release: Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitryps...
Jefferies reiterates Buy rating on Sanofi stock despite FDA setback for tolebrutinib - Investing.com
Jefferies reiterates Buy rating on Sanofi stock despite FDA setback for tolebrutinib Investing.com
Sanofi Reaches Deals with ADEL for Novel Alzheimer’s Disease Drug, Dren Bio for B-cell Depletion ...
Sanofi Reaches Deals with ADEL for Novel Alzheimer’s Disease Drug, Dren Bio for B-cell Depletion Therapy Pharmaceutical Executive
Sanofi to buy Dynavax for $15.50 per share (SNY:NASDAQ) - Seeking Alpha
Sanofi to buy Dynavax for $15.50 per share (SNY:NASDAQ) Seeking Alpha
Sanofi stock slides on Dupixent successor AD trial - Clinical Trials Arena
Sanofi stock slides on Dupixent successor AD trial Clinical Trials Arena
NANOBODY® Technology Platform - Sanofi
French authorities raid Sanofi headquarters in tax fraud probe - Fierce Pharma
French authorities raid Sanofi headquarters in tax fraud probe Fierce Pharma
BP to sell 65% of Castrol stake, Sanofi's $2.2B deal for Dynavax - Yahoo Finance
BP to sell 65% of Castrol stake, Sanofi's $2.2B deal for Dynavax Yahoo Finance
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved ...
Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey Dassault Systèmes
Sanofi Ventures bets on AI with $625m cash influx - - Global Venturing
Sanofi Ventures bets on AI with $625m cash influx - Global Venturing
Sanofi's type 1 diabetes drug recommended for EU approval - Reuters
Sanofi's type 1 diabetes drug recommended for EU approval Reuters
ESMO 2025 preview – Sanofi’s lead shot gets a boost | ApexOnco - Clinical Trials news and analysi...
ESMO 2025 preview – Sanofi’s lead shot gets a boost | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales - BioPharma Dive
Sanofi says ‘soft’ start to fall immunizations slowed vaccine sales BioPharma Dive
Sanofi inks $500M deal with Evoq for next-gen autoimmune tech - Fierce Biotech
Sanofi inks $500M deal with Evoq for next-gen autoimmune tech Fierce Biotech
Does Sanofi’s Falling Share Price Reveal Opportunity Following R&D Pipeline Progress? - Yahoo Fin...
Does Sanofi’s Falling Share Price Reveal Opportunity Following R&D Pipeline Progress? Yahoo Finance
Sanofi set to offer insulin products at $35 per month for all US patients - Reuters
Sanofi set to offer insulin products at $35 per month for all US patients Reuters
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness - ...
Texas sues Bristol Myers, Sanofi for concealing blood thinner Plavix's alleged ineffectiveness Reuters
Sanofi licenses Korean biotech’s tau-targeting Alzheimer’s drug for $80M upfront - Endpoints News
Sanofi licenses Korean biotech’s tau-targeting Alzheimer’s drug for $80M upfront Endpoints News
Sanofi expands $35-per-month pricing to all insulin products - Fierce Pharma
Sanofi expands $35-per-month pricing to all insulin products Fierce Pharma
ESMO 2025 – Sanofi takes aim at Lutathera | ApexOnco - Clinical Trials news and analysis - Oncolo...
ESMO 2025 – Sanofi takes aim at Lutathera | ApexOnco - Clinical Trials news and analysis Oncology Pipeline
Press Release: Sanofi provides update on tolebrutinib - GlobeNewswire
Press Release: Sanofi provides update on tolebrutinib GlobeNewswire
Sanofi multiple sclerosis drug rejected in U.S. (SNY:NASDAQ) - Seeking Alpha
Sanofi multiple sclerosis drug rejected in U.S. (SNY:NASDAQ) Seeking Alpha
Digital Transformation and Artificial Intelligence - Sanofi
For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales - Fierce Pharma
For Sanofi, Dupixent's surge overcomes shortfall in vaccine sales Fierce Pharma